ANI Pharmaceuticals Inc
ANIP
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
166.6% downsideOvervalued by 166.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.87 Billion |
|---|---|
| Enterprise Value | $1.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.5 |
| Beta | 0.43 |
| Outstanding Shares | 20,914,000 |
Return
| Return on Equity | 16.68% |
|---|---|
| Return on Assets | 6.60% |
| Return on Invested Capital | 11.72% |
Valuation & Multiples
| P/E Ratio | 19.97 |
|---|---|
| PEG | 22.67 |
| Price to Sales | 1.87 |
| Price to Book Ratio | 3.16 |
| Enterprise Value to Revenue | 2.04 |
| Enterprise Value to EBIT | 13.62 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 206.12% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.29%▼ 116.34% |
|---|---|
| Total Invested | $5.06M▼ 99.72% |
| Investors Holding | 8▼ 278.00% |
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...
Relevant Senate Committees
The most influential committee for pharma; controls Medicare and Medicaid pricing, rebates, and the tax policies that dictate corporate profitability.
Determines the funding levels for the FDA and the Department of Health and Human Services, impacting drug review speeds and federal procurement budgets.
Directly oversees the FDA; regulates the drug approval process for both generics and branded biological products, which is fundamental to ANI's operations.
Oversees intellectual property and antitrust law; critical for ANI's generic business model which relies on patent challenges and navigating IP litigation.
Frequently investigates drug pricing and generic accessibility; hearings can create significant headline risk and drive legislative momentum for price controls.
The VA is a major purchaser of generic and branded pharmaceuticals; committee decisions on drug formularies and funding directly impact revenue streams.